|
|
Latest Non-Hodgkin's Lymphoma News
September Is National Leukemia and Lymphoma Awareness Month (8/28/2009)
As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Veltuzumab Effective for Refractory Non-Hodgkin’s Lymphoma (7/28/2009)
Veltuzumab is safe and effective for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma, according to the results of a study published in the Journal of Clinical Oncology.
Allogeneic Stem Cell Transplantation Effective for Angioimmunoblastic T-Cell Lymphoma (7/27/2009)
Among patients with a type of T-cell non-Hodgkin’s lymphoma known as angioimmunoblastic T-cell lymphoma (AITL), treatment with allogeneic stem cell transplantation results in long-term disease-free survival in approximately 50% of patients. The results of this study were published in the Journal of Clinical Oncology.
Idiotype Vaccine Improves Disease-free Survival in Patients with Follicular Lymphoma (6/8/2009)
BiovaxID, an individualized tumor-specific protein vaccine, prolongs disease-free survival in patients with advanced follicular lymphoma who experience complete remission for six months or longer following first-line treatment with the chemotherapy regimen PACE, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.
Additional Evidence That Antibiotics Are Effective Against Gastric MALT Lymphomas (5/29/2009)
According to the results of a study published in the Annals of Oncology, antibiotic treatment of Helicobacter pylori infection results in a high rate of long-term survival among patients with localized, gastric MALT lymphoma.
Non-Hodgkin's Lymphoma News By Topic
Non-Hodgkin's Lymphoma - Screening/PreventionSeptember Is National Leukemia and Lymphoma Awareness Month (8/28/2009)
As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Cyclophosphamide May Increase Cancer Risk Among Patients with Rheumatoid Arthritis (3/10/2008)
A large study conducted in Canada reveals that patients who are treated for rheumatoid arthritis (RA) with the drug cyclophosphamide may have an increased risk for developing hematological cancers such as lymphoma.
Being Overweight Associated with Increased Risk of Several Cancers (2/19/2008)
Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet.
Hepatitis C Virus May Increase Risk of Non-Hodgkin’s Lymphoma (5/10/2007)
According to the results of a study published in the Journal of the American Medical Association, individuals who are infected with the hepatitis C virus are 20–30% more likely than non-infected individuals to develop non-Hodgkin’s lymphoma.
No Clear Link Between Allergy and Non-Hodgkin’s Lymphoma (1/17/2007)
According to the results of studies conducted in Denmark, Sweden, and Finland, allergy does not appear to influence the risk of developing non-Hodgkin’s lymphoma. These results were published in the Journal of the National Cancer Institute.
Non-Hodgkin's Lymphoma - Indolent/Low GradeIdiotype Vaccine Improves Disease-free Survival in Patients with Follicular Lymphoma (6/8/2009)
BiovaxID, an individualized tumor-specific protein vaccine, prolongs disease-free survival in patients with advanced follicular lymphoma who experience complete remission for six months or longer following first-line treatment with the chemotherapy regimen PACE, according to the results of a study presented at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.
Additional Evidence That Antibiotics Are Effective Against Gastric MALT Lymphomas (5/29/2009)
According to the results of a study published in the Annals of Oncology, antibiotic treatment of Helicobacter pylori infection results in a high rate of long-term survival among patients with localized, gastric MALT lymphoma.
Maintenance Rituxan® Prolongs Survival in Advanced Indolent Lymphoma (3/24/2009)
Maintenance Rituxan® (rituximab) given after standard chemotherapy significantly prolongs progression-free survival (PFS) in patients with advanced-stage indolent non-Hodgkin’s lymphoma, according to the results of a study published in the Journal of Clinical Oncology.
Advances in the Treatment of Low-grade Non-Hodgkin’s Lymphoma (2/5/2009)
Recent advances in the treatment of low-grade non-Hodgkin’s lymphoma (NHL) have led to improvements in progression-free and overall survival. Research presented at the 2008 ASH meeting highlighted further progress in this area.
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia (2/2/2009)
At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
Non-Hodgkin's Lymphoma - Aggressive/Intermediate GradeAdvances in the Treatment of Aggressive Non-Hodgkin’s Lymphoma (2/6/2009)
A Report from the 2008 Meeting of the American Society of Hematology
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia (2/2/2009)
At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology (1/26/2009)
The 2008 ASH meeting featured several reports of new agents that are showing promise in the treatment of Non-Hodgkin’s Lymphoma.
Survival Rates Improving in Childhood Hematologic Cancers (9/29/2008)
Five- and 10-year survival rates in childhood hematalogic cancers have significantly improved since 1990, according to the results of a study recently published in the Journal of the National Cancer Institute.
ER-CHOP Promising for Diffuse Large B-Cell NHL (9/17/2008)
The treatment combination consisting of epratuzumab, Rituxan® (rituximab), and the chemotherapy combination referred to as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) provides high anticancer responses when used as initial therapy for the treatment of diffuse large B-cell lymphoma. These findings were recently reported in the Journal of Clinical Oncology.
Non-Hodgkin's Lymphoma - Highly Aggressive/High GradeThe American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia (2/2/2009)
At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology (1/26/2009)
The 2008 ASH meeting featured several reports of new agents that are showing promise in the treatment of Non-Hodgkin’s Lymphoma.
Survival Rates Improving in Childhood Hematologic Cancers (9/29/2008)
Five- and 10-year survival rates in childhood hematalogic cancers have significantly improved since 1990, according to the results of a study recently published in the Journal of the National Cancer Institute.
Smoking and Heavy Alcohol Consumption Reduce Survival in Non-Hodgkin's Lymphoma (5/13/2008)
Patients diagnosed with non-Hodgkin’s lymphoma (NHL) who smoke tobacco products and/or drink large quantities of alcohol have a reduced chance of optimal survival. These results were recently published in the International Journal of Cancer.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma (4/1/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Non-Hodgkin's Lymphoma - RecurrentVeltuzumab Effective for Refractory Non-Hodgkin’s Lymphoma (7/28/2009)
Veltuzumab is safe and effective for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma, according to the results of a study published in the Journal of Clinical Oncology.
New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology (1/26/2009)
The 2008 ASH meeting featured several reports of new agents that are showing promise in the treatment of Non-Hodgkin’s Lymphoma.
Treanda® Approved for Recurrent NHL (11/3/2008)
The United States Food and Drug Administration has approved Treanda® (bendamustine hydrochloride) for the treatment of slow-growing (indolent) B-cell non-Hodgkin's lymphoma (NHL) that has progressed either during therapy or within six months of therapy including Rituxan® (rituximab). Treanda is already approved for the treatment of chronic lymphocytic leukemia (CLL).
Zevalin® Effective for Treatment of Cutaneous B-Cell Lymphoma (8/25/2008)
Zevalin® (Yttrium-90 [(90)Y] ibritumomab tiuxetan) appears highly effective in the treatment of primary cutaneous B-cell lymphoma (PCBCL). The details of this study appeared in an early online publication in Leukemia-Lymphoma on July 25, 2008.
Zevalin® Effective for Patients with Follicular Lymphoma Following an Autologous Transplant (8/25/2008)
Zevalin® (Yttrium-90 [(90)Y] ibritumomab tiuxetan) appears to provide effective, long-term anticancer responses for patients with follicular lymphoma whose cancer has progressed following an autologous stem cell transplant. The details of this small study appeared in an early online publication of Leukemia-Lymphoma of July 15, 2008.
Non-Hodgkin's Lymphoma - T-CellAllogeneic Stem Cell Transplantation Effective for Angioimmunoblastic T-Cell Lymphoma (7/27/2009)
Among patients with a type of T-cell non-Hodgkin’s lymphoma known as angioimmunoblastic T-cell lymphoma (AITL), treatment with allogeneic stem cell transplantation results in long-term disease-free survival in approximately 50% of patients. The results of this study were published in the Journal of Clinical Oncology.
Pralextrate Continues to Show Benefit in Treatment of Peripheral T-Cell Lymphoma (2/10/2009)
According to the final results of a Phase II clinical trial, 27% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin’s lymphoma) experienced a complete or partial disappearance of detectable cancer following treatment with the investigational drug pralatrexate; the median duration of response was over nine months.
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia (2/2/2009)
At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
Pralatrexate Shows Promise Against Peripheral T-cell Lymphoma (12/10/2008)
In a Phase II clinical trial, 27% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin’s lymphoma) experienced a complete or partial disappearance of detectable cancer following treatment with the investigational drug pralatrexate. These results were presented at the 50th Annual Meeting of the American Society of Hematology.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma (4/1/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Non-Hodgkin's Lymphoma - Mantle CellThe American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia (2/2/2009)
At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
Intensive Chemotherapy Prolongs Remission of Mantle Cell Lymphoma (12/12/2008)
In a study of intensive chemotherapy for mantle cell lymphoma, more than half of patients 65 or younger were still in remission after seven years. These results were presented at the 50th Annual Meeting of the American Society of Hematology.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma (4/1/2008)
Statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL), according to a recently published article in PLoS Med (the Public Library of Science journal).
Non-Hodgkin’s Lymphoma Survivors May Suffer Symptoms of Post Traumatic Stress (2/26/2008)
Patients who have been diagnosed and treated for non-Hodgkin’s lymphoma may have symptoms of post traumatic stress disorder (PTSD). These finding were recently published in the Journal of Clinical Oncology.
Long-term Quality-of-life Issues Persist Among Non-Hodgkin’s Lymphoma Survivors (4/11/2007)
According to an article recently published in the journal Cancer, long-term survivors of non-Hodgkin’s lymphoma have quality-of-life concerns that deserve attention following treatment.
|
|
